Bacteriophage virus-like particle vaccines for Chlamydia trachomatis urogenital infection
Bacteriophage virus-like particle vaccines for Chlamydia trachomatis urogenital infection
批准号:
10584334
负责人:
Kathryn M. Frietze
金额:
$38.31万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-12-06 至 2027-11-30
关键词:
AdhesionsAnimal ModelAntibiotic TherapyAntibodiesAntibody ResponseAntibody SpecificityAntibody titer measurementAntibody-mediated protectionAntigensAutomobile DrivingBacteriaBacteriophagesBindingCD4 Positive T LymphocytesCell Culture TechniquesCellsChlamydiaChlamydia InfectionsChlamydia trachomatisComplementDataEctopic PregnancyEngineeringEpitopesFemaleGenitourinary System InfectionGenitourinary systemGoalsHumanImmuneImmune SeraImmune responseImmunityImmunizationImmunizeIn VitroInfectionInfertilityInterferon Type IIKnowledgeLicensingMediatingMucous MembraneMusNatureOryctolagus cuniculusPassive Transfer of ImmunityPathologyPelvic Inflammatory DiseasePeptidesPhagocytesPrevalencePreventive vaccineProteinsPublishingRecording of previous eventsResearchRoleSafetySexually Transmitted DiseasesT cell responseT-LymphocyteTest ResultTestingUnited States National Institutes of HealthVaccine DesignVaccinesVirus-like particleWomanWorkantibody testchlamydia vaccinedesigneffective therapyexperienceimmunogenicimmunogenicityin vitro Assayin vivoinnovationinterestlong-term sequelaemajor outer membrane proteinmalemouse modelneutrophilnovelnovel strategiesprophylacticreproductive tractresponsescreening programtreatment programtubal infertilityuptakeurogenital tractvaccine accessvaccine candidatevaccine developmentvaccine platformvaccine strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Chlamydia trachomatis is an obligate intracellular bacteria that is the most common bacterial sexually transmitted
infection. Despite effective antibiotic treatment and screening programs, the prevalence of chlamydia continues
to rise. Although the infection can be asymptomatic, some women experience serious long-term sequelae,
including pelvic inflammatory disease, infertility, and ectopic pregnancy. For these reasons, a prophylactic
vaccine against chlamydia is needed. However, significant gaps exist in our knowledge of the natural immune
response to urogenital Chlamydia trachomatis infection. In particular, the specificity of antibodies elicited during
infection, their functions, and their protective capacity are not well understood. The overall goal of this research
is to design prophylactic antibody-eliciting vaccines against urogenital Chlamydia trachomatis infection. The
objective of this proposal is to define the range of protective functions antibodies can have against Chlamydia
trachomatis infection of the female urogenital tract, and use this knowledge to create vaccines that can elicit
those antibodies. Our working hypothesis is that antibody responses that target proteins known to be involved
in adhesion and entry into host cells or mediate pathology in the reproductive tract will be protective against
urogenital Chlamydia trachomatis infection. In Aim 1, we will engineer epitope-specific vaccine candidates that
will elicit high titer antibodies to Chlamydia trachomatis adhesion factors and define their immunogenicity in
mouse immunization studies. In Aim 2, we will investigate the specific functions of vaccine-elicited antibodies to
neutralize Chlamydia trachomatis infection in cell culture, mediate complement killing of Chlamydia trachomatis,
and facilitate uptake and killing by neutrophils. In Aim 3, we will investigate the protective capacity of our vaccines
in mouse models of Chlamydia infection. We will investigate the bacterial burden in the upper reproductive tract,
bacterial shedding, pathology, and male urogenital tract infection. Overall, these studies will define the role of
epitope-specific antibodies in urogenital Chlamydia trachomatis infection and lead to the identification of novel
targets for Chlamydia trachomatis vaccine design.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bacteriophage virus-like particle vaccines against dengue virus non-structural protein 1
-
批准号:10056169
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2020
-
负责人:Kathryn M. Frietze
-
依托单位:
海外基金